HRP20161266T1 - Dijagnoza i liječenje preeklampsije - Google Patents
Dijagnoza i liječenje preeklampsije Download PDFInfo
- Publication number
- HRP20161266T1 HRP20161266T1 HRP20161266TT HRP20161266T HRP20161266T1 HR P20161266 T1 HRP20161266 T1 HR P20161266T1 HR P20161266T T HRP20161266T T HR P20161266TT HR P20161266 T HRP20161266 T HR P20161266T HR P20161266 T1 HRP20161266 T1 HR P20161266T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- use according
- composition
- microglobulin
- solid
- Prior art date
Links
- 201000011461 pre-eclampsia Diseases 0.000 title claims 3
- 238000011282 treatment Methods 0.000 title claims 3
- 238000003745 diagnosis Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102000003966 Alpha-1-microglobulin Human genes 0.000 claims 4
- 101800001761 Alpha-1-microglobulin Proteins 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/99—Miscellaneous (1.14.99)
- C12Y114/99003—Heme oxygenase (1.14.99.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Marine Sciences & Fisheries (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
Claims (10)
1. Alfa 1-mikroglobulin za uporabu u profilazi ili liječenju preeklampsije.
2. Farmaceutski sastav koji sadrži alfa 1-mikroglobulin za uporabu u profilazi ili liječenju preeklampsije.
3. Farmaceutski sastav za uporabu prema zahtjevu 2, gdje je farmaceutski sastav za parenteralnu uporabu.
4. Farmaceutski sastav za uporabu prema zahtjevu 2, gdje je farmaceutski sastav za oralnu uporabu.
5. Farmaceutski sastav za upotrebu prema zahtjevu 3, pri čemu je ruta administracije parenteralna ruta odabrana iz liste koja se sastoji od intravenozne, intraperitonealne, intramuskularne i potkožne injekcije.
6. Farmaceutski sastav prema zahtjevu 3 ili 5 u obliku tekućeg sastava ili krutog sastava dizajniranog da se rekonstituira npr. s vodom prije administracije.
7. Farmaceutski sastav za uporabu prema zahtjevu 2 koji nadalje sadrži antitijelo, matičnu stanicu ili rekombinantnu stanicu koja cilja spomenuti alfa 1-mikroglobulin na placentu.
8. Farmaceutski sastav za uporabu prema zahtjevu 4, gdje je sastav u krutom, semi-krutom ili tekućem obliku.
9. Farmaceutski sastav za uporabu prema zahtjevu 8, gdje je sastav kruti dozni oblik, puderi, granule, peleti, granule, sirupi, smjese, suspenzije ili emulzije.
10. Farmaceutski sastav koji sadrži alfa-1-mikroglobulin za uporabu kao lijek.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0700339 | 2007-02-12 | ||
| EP13160275.7A EP2614832B1 (en) | 2007-02-12 | 2008-02-12 | Diagnosis and treatment of preeclampsia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161266T1 true HRP20161266T1 (hr) | 2016-12-16 |
Family
ID=39295873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130809AT HRP20130809T1 (en) | 2007-02-12 | 2013-08-28 | Diagnosis of preeclampsia |
| HRP20161266TT HRP20161266T1 (hr) | 2007-02-12 | 2016-10-03 | Dijagnoza i liječenje preeklampsije |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130809AT HRP20130809T1 (en) | 2007-02-12 | 2013-08-28 | Diagnosis of preeclampsia |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8568999B2 (hr) |
| EP (3) | EP2111555B1 (hr) |
| JP (2) | JP5604111B2 (hr) |
| KR (2) | KR101608501B1 (hr) |
| AU (1) | AU2008214837B2 (hr) |
| BR (1) | BRPI0808340A2 (hr) |
| CA (1) | CA2674204C (hr) |
| DK (2) | DK2614832T3 (hr) |
| EA (2) | EA031877B1 (hr) |
| ES (2) | ES2599003T3 (hr) |
| HR (2) | HRP20130809T1 (hr) |
| HU (1) | HUE031613T2 (hr) |
| MX (2) | MX2009008408A (hr) |
| NZ (1) | NZ578077A (hr) |
| PL (2) | PL2614832T3 (hr) |
| PT (2) | PT2111555E (hr) |
| WO (1) | WO2008098734A1 (hr) |
| ZA (1) | ZA200905101B (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008214837B2 (en) * | 2007-02-12 | 2013-01-10 | A1M Pharma Ab | Diagnosis and treatment of preeclampsia |
| EP2313106B1 (en) * | 2008-07-18 | 2016-03-30 | A1M Pharma AB | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
| WO2011095981A1 (en) * | 2010-02-03 | 2011-08-11 | St. John's Research Institute | An in-vitro method for characterizing hemoglobin variant |
| PT2550535E (pt) * | 2010-03-24 | 2015-09-07 | Preelumina Diagnostics Ab | Hbf e a1m como marcadores de fase inicial para pré- eclâmpsia |
| CN103069277B (zh) * | 2010-03-31 | 2016-03-30 | 积水医疗株式会社 | 利用免疫色谱法的测定法、免疫色谱测试条和用于免疫色谱法的测定试剂盒 |
| CA2886489A1 (en) | 2011-10-14 | 2013-04-18 | Aarhus Universitet | Diagnostic and prognostic use of prombp-complexes |
| CA2881321A1 (en) * | 2012-09-05 | 2014-03-13 | A1M Pharma Ab | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases |
| US10928402B2 (en) | 2012-12-28 | 2021-02-23 | Nx Prenatal Inc. | Treatment of spontaneous preterm birth |
| US20140186332A1 (en) * | 2012-12-28 | 2014-07-03 | NX Pharmagen | Biomarkers of preterm birth |
| MX2017011198A (es) | 2015-03-16 | 2018-02-19 | A1M Pharma Ab | Biomarcadores para preeclampsia. |
| KR101732933B1 (ko) | 2015-07-29 | 2017-05-08 | 영남대학교 산학협력단 | 신생아의 성장 또는 심혈관계 질환 예후 진단 방법 |
| JP2019505815A (ja) | 2015-12-04 | 2019-02-28 | エヌエックス・プリネイタル・インコーポレイテッドＮＸ Ｐｒｅｎａｔａｌ Ｉｎｃ． | 自然早産リスクを層別化するための循環マイクロ粒子の使用 |
| ES2969882T3 (es) | 2018-03-19 | 2024-05-23 | Regeneron Pharma | Ensayos y reactivos de electroforesis capilar en microchip |
| US11418353B2 (en) * | 2019-08-26 | 2022-08-16 | Micron Technology, Inc. | Security descriptor generation |
| CN111626280B (zh) * | 2020-04-13 | 2021-09-07 | 北京邮电大学 | 一种无定位点答题卡识别方法和装置 |
| WO2024053586A1 (ja) * | 2022-09-05 | 2024-03-14 | 栄研化学株式会社 | 遊離ヘモグロビン測定試薬、遊離ヘモグロビン測定方法および抗ヘモグロビン抗体 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1337778A1 (ru) | 1984-06-25 | 1987-09-15 | Новосибирский государственный медицинский институт | Способ диагностики т жести позднего токсикоза беременных |
| US5079171A (en) | 1988-09-15 | 1992-01-07 | Adeza Biomedical Corporation | Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin |
| US5238819A (en) | 1988-12-14 | 1993-08-24 | The Regents Of The University Of California | Diagnostic assay for the detection of preeclampsia |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5108898A (en) | 1989-01-18 | 1992-04-28 | Peters John H | Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy |
| US5612034A (en) * | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
| US5166133A (en) | 1991-04-17 | 1992-11-24 | Cetus Corporation | Method for inhibing adhesion of white blood cells to endothelial cells |
| US6103691A (en) | 1994-03-23 | 2000-08-15 | Tschesche; Harald | Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins |
| US5849474A (en) * | 1995-12-06 | 1998-12-15 | Olson; Camilla M. | Diagnosis of preeclampsia in mammals |
| US5910482A (en) * | 1996-03-19 | 1999-06-08 | Board Of Regents, The University Of Texas System | Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor |
| US6169816B1 (en) * | 1997-05-14 | 2001-01-02 | Applied Imaging, Inc. | Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images |
| JP2001348342A (ja) | 2001-04-12 | 2001-12-18 | Nippon Zoki Pharmaceut Co Ltd | 免疫調整・抗炎症剤 |
| ATE439588T1 (de) | 2001-05-04 | 2009-08-15 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
| DE60219642T2 (de) | 2001-09-04 | 2008-01-17 | Iq Corp. B.V. | Bestimung und quantifizierung von erythrocytenpopulation in proben |
| JPWO2003083479A1 (ja) * | 2002-03-29 | 2005-08-04 | 松下電器産業株式会社 | 血液処理方法、血液処理デバイス、ヘモグロビン類測定方法およびヘモグロビン類測定デバイス |
| DE10237423A1 (de) | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| EP1638605B1 (en) * | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| AR045074A1 (es) | 2003-07-23 | 2005-10-12 | Applied Research Systems | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes |
| CA2547124A1 (en) * | 2003-11-26 | 2005-06-09 | Sanofi-Aventis Deutschland Gmbh | Tubular proteinuria as an indicator for elevated cardiovascular risk |
| WO2005093413A2 (en) | 2004-03-22 | 2005-10-06 | Yale University | Diagnosis and treatment of preeclampsia |
| US20070292421A1 (en) * | 2005-07-28 | 2007-12-20 | Feinberg Bruce B | Method for treating preeclampsia |
| GB0600916D0 (en) | 2006-01-17 | 2006-02-22 | Perkinelmer Instr Las Inc | detecting and predicting pre-eclampsia |
| CA2636353A1 (en) * | 2006-01-18 | 2007-07-26 | Georg Wick | Test systems for the analysis of polypeptides and cells adhering to silicones |
| AU2008214837B2 (en) | 2007-02-12 | 2013-01-10 | A1M Pharma Ab | Diagnosis and treatment of preeclampsia |
| WO2009108073A1 (en) | 2008-02-28 | 2009-09-03 | Auckland Uniservices Limited | Biomarkers for prediction of preeclampsia and/or cardiovascular disease |
| EP2313106B1 (en) | 2008-07-18 | 2016-03-30 | A1M Pharma AB | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
| PT2550535E (pt) | 2010-03-24 | 2015-09-07 | Preelumina Diagnostics Ab | Hbf e a1m como marcadores de fase inicial para pré- eclâmpsia |
-
2008
- 2008-02-12 AU AU2008214837A patent/AU2008214837B2/en not_active Ceased
- 2008-02-12 EP EP08707674.1A patent/EP2111555B1/en not_active Not-in-force
- 2008-02-12 KR KR1020147017284A patent/KR101608501B1/ko active IP Right Grant
- 2008-02-12 PL PL13160275T patent/PL2614832T3/pl unknown
- 2008-02-12 EA EA201500335A patent/EA031877B1/ru not_active IP Right Cessation
- 2008-02-12 JP JP2009548631A patent/JP5604111B2/ja not_active Expired - Fee Related
- 2008-02-12 MX MX2009008408A patent/MX2009008408A/es active IP Right Grant
- 2008-02-12 US US12/526,941 patent/US8568999B2/en not_active Expired - Fee Related
- 2008-02-12 EA EA200970758A patent/EA022609B1/ru not_active IP Right Cessation
- 2008-02-12 ES ES13160275.7T patent/ES2599003T3/es active Active
- 2008-02-12 WO PCT/EP2008/001051 patent/WO2008098734A1/en active Application Filing
- 2008-02-12 MX MX2013001577A patent/MX347788B/es unknown
- 2008-02-12 ES ES08707674T patent/ES2426069T3/es active Active
- 2008-02-12 DK DK13160275.7T patent/DK2614832T3/da active
- 2008-02-12 PT PT87076741T patent/PT2111555E/pt unknown
- 2008-02-12 DK DK08707674.1T patent/DK2111555T3/da active
- 2008-02-12 HU HUE13160275A patent/HUE031613T2/en unknown
- 2008-02-12 EP EP13160275.7A patent/EP2614832B1/en not_active Not-in-force
- 2008-02-12 KR KR1020097019056A patent/KR101454013B1/ko active IP Right Grant
- 2008-02-12 PL PL08707674T patent/PL2111555T3/pl unknown
- 2008-02-12 EP EP13160278.1A patent/EP2613150A1/en not_active Withdrawn
- 2008-02-12 NZ NZ578077A patent/NZ578077A/en not_active IP Right Cessation
- 2008-02-12 BR BRPI0808340A patent/BRPI0808340A2/pt not_active Application Discontinuation
- 2008-02-12 CA CA2674204A patent/CA2674204C/en not_active Expired - Fee Related
- 2008-02-12 PT PT131602757T patent/PT2614832T/pt unknown
-
2009
- 2009-07-21 ZA ZA2009/05101A patent/ZA200905101B/en unknown
-
2013
- 2013-07-19 JP JP2013150603A patent/JP5792772B2/ja not_active Expired - Fee Related
- 2013-08-28 HR HRP20130809AT patent/HRP20130809T1/hr unknown
- 2013-09-17 US US14/028,971 patent/US20140065170A1/en not_active Abandoned
-
2016
- 2016-10-03 HR HRP20161266TT patent/HRP20161266T1/hr unknown
-
2018
- 2018-01-26 US US15/880,943 patent/US10359406B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161266T1 (hr) | Dijagnoza i liječenje preeklampsije | |
| BRPI0710485B1 (pt) | composições líquidas úteis no tratamento de doenças respiratórias | |
| HRP20211899T1 (hr) | Formulacija protutijela | |
| HRP20180445T1 (hr) | Il-22 za uporabu u liječenju mikrobnih poremećaja | |
| JP2015518818A5 (hr) | ||
| HRP20150790T1 (hr) | Režimi imunoterapije koji ovise o statusu apoe | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| AR092779A1 (es) | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau | |
| BR112012017054A2 (pt) | "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica" | |
| BRPI0408490A (pt) | composições que compreendem ácidos graxos e aminoácidos | |
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| JP2015517488A5 (hr) | ||
| BR112013000842A2 (pt) | composições farmacêuticas, método de tratamento de condição de etiologia funcional do trato gastrointestinal e uso de forma potenciada ativada de anticorpo para a proteína s-100, de forma potenciada ativada de anticorpo para histamina e de forma potenciada ativada de anticorpo para a tnf-alfa. | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| BR112015015864A2 (pt) | composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica | |
| HRP20210552T1 (hr) | Liječenje multiplog mijeloma (mm) | |
| CL2007003468A1 (es) | Sal de potasio cristalina de analogos de lipoxina a4; metodode sintesis; composicion farmaceutica; y uso en el tratamiento de trastornos inflamatorios o autoinmunes. | |
| BR112014028654A2 (pt) | composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos | |
| UY33258A (es) | Proteinas de union a antigeno | |
| JP2010281322A5 (hr) | ||
| HRP20191434T1 (hr) | Liječenje eritromelalgije | |
| BR112015022196A2 (pt) | composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos | |
| TN2009000088A1 (en) | Packaging system for pharmaceutical compositions and kit for intravenous administration | |
| BR112015022398A2 (pt) | formas de dosagem sólidas de liberação estendida de antieméticos | |
| CL2013002056A1 (es) | Compuestos derivados de 2-metoxi-piridin-4-ilo; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades asociadas a un sistema inmune activado, tales como rechazo de organos transplantados, artritis reumatoide, enfermedad de crohn, entre otras. |